This is a routine procedural loss with no material impact on Teva's stock. The underlying antitrust case continues — monitor for summary judgment motions or trial dates, which would be the next material catalysts.
Price Chart
Executive Summary
Teva lost a discovery dispute in its antitrust/physician-payment lawsuit against Corcept Therapeutics. The court denied Teva's motion to compel production of text messages from Corcept's DOJ production, finding Teva failed to show the messages were relevant or proportional. This is a minor procedural setback in a pending case — no damages, no injunction, no change to the underlying claims.
Court Ruling Details
Key Facts
- Teva sued Corcept alleging anticompetitive physician payments to induce prescriptions of Korlym over Teva's generic mifepristone.
- Teva moved to compel Corcept to produce text messages from a prior DOJ production regarding physician payments.
- The court denied the motion, ruling Teva did not show the text messages were relevant or proportional to the case.
- The ruling is a discovery dispute resolution — no damages awarded, no injunction issued, no claims dismissed.
- The case (5:24-cv-03567-NW) remains active in the Northern District of California.
Financial Impact
No financial impact — discovery ruling only, no damages or exposure stated.
Risk Factors
- Teva's antitrust claims against Corcept remain pending and could result in damages or injunctive relief if Teva ultimately prevails.
- Corcept's motion practice may delay resolution of the case, extending legal costs and uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-dec579e875-TEVA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.29 (+8.09%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.29 (+6.88%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.29 (+4.80%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.29 (+7.82%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.29 (+8.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.29 (+12.87%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.29 (+12.23%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.29 (+13.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access